News and Trends 26 Nov 2018
First Gene Therapy for Inherited Blindness Approved in Europe
Novartis has received approval for Luxturna, a gene therapy that can restore vision in people with a specific genetic mutation…
Novartis
- Latest Posts
Interview 3 Sep 2018
Moving from Big Pharma to Biotech – Insights from Two Biotech CEOs
According to John LaMattina in Forbes last year, more and more senior scientific executives are moving from pharma to small…
News and Trends 23 Apr 2018
The First CAR-T Therapy Is Not Living Up to Commercial Expectations
Novartis' Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news…
News and Trends 19 Feb 2018
Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown?
Two clinical studies have demonstrated the capacity of Novartis' monoclonal antibody to treat both plaque and scalp psoriasis and improve…
ADVERTISEMENT
News and Trends 25 Jan 2018
Novartis Will Bring US Gene Therapy for Blindness to Europe
The Swiss pharma has bought into the gene editing therapy game in a deal with Spark worth $170M (€137M) for…
In Depth 25 Jan 2018
What Happened to the Plans for a Smart Contact Lens for Diabetics?
Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google…
News and Trends 22 Jan 2018
Novartis Takes Genmab’s Leukemia Drug Off the Market
Genmab's leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as…
Best in Biotech 18 Dec 2017
Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017
Now that we've got the bad news out of the way, we're here to spread some Christmas cheer with the…
News and Trends 31 Aug 2017
The FDA Approves the First CAR-T Cell Therapy for Cancer
The FDA has approved Novartis' CAR-T therapy Kymriah, opening the way for a new generation of cell therapy treatments against…
News and Trends 29 Aug 2017
Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks
European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the…
ADVERTISEMENT
News and Trends 11 Jul 2017
Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns
Editor's Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application…
News and Trends 22 Jun 2017
Novartis Scores Major Phase III Win with New Cardiovascular Drug
Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis…
News and Trends 20 Jun 2017
Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials
Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD.…
News and Trends 15 Jun 2017
Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx
Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling…
News and Trends 15 Jun 2017
UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech
The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google's Verily to invest in…
News and Trends 2 May 2017
Novartis Gains Access to Celyad’s allogenic CAR-T cell patents
Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license…
ADVERTISEMENT
News and Trends 25 Apr 2017
Novartis Negotiates its Way into the US Migraine Market
Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk…
News and Trends 19 Apr 2017
UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement
UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Novartis and…
News and Trends 18 Apr 2017
Two Big Pharma Players Team up to Take Over the NASH Space
Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis' FXR agonist…
Best in Biotech 18 Apr 2017
The Top 12 Biotech Leaders You Should Know in Basel
After exploring Munich and the Golden Triangle, we head to another biotech hotspot full of people that should be on your…